Update on medical management of atrial fibrillation in the modern era

Heart Rhythm

Volumn 6, Issue 8 SUPPL., 2009, Pages

  Gopinathannair, Rakesh ^a   Sullivan, Renee M ^a   Olshansky, Brian ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Medical management; Rate control; Rhythm control

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DABIGATRAN; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; HEPARIN; IDRAPARINUX; PROPAFENONE; QUINIDINE; RIVAROXABAN; SOTALOL; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTICLE; BLEEDING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; PATIENT SAFETY; PRIORITY JOURNAL; SINUS RHYTHM; STROKE; THROMBOEMBOLISM;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; HEART RATE; HUMANS; STROKE;

EID: 67651152574     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2009.02.013     Document Type: Article

References (66)

1. Kirchhof P., Auricchio A., Bax J., et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 9 (2007) 1006-1023
2. Rockson S.G., and Albers G.W. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 43 (2004) 929-935
3. Hart R.G., Benavente O., McBride R., et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131 (1999) 492-501
4. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006) e257-e354
5. Rietbrock S., Heeley E., Plumb J., et al. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 156 (2008) 57-64
6. Willems R., and Exner D.V. Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials?. J Interv Card Electrophysiol 10 Suppl 1 (2004) 9-16
7. Go A.S., Hylek E.M., Borowsky L.H., et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 131 (1999) 927-934
8. Hylek E.M., Evans-Molina C., Shea C., et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115 (2007) 2689-2696
9. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370 (2007) 493-503
10. Gallagher A.M., Rietbrock S., Plumb J., et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. J Thromb Haemost 6 (2008) 1500-1506
11. Guo H., Shaheen W., Kerber R., and Olshansky B. Cardioversion of atrial tachyarrhythmias: anticoagulation to reduce thromboembolic complications. Prog Cardiovasc Dis 46 (2004) 487-505
12. Olshansky B., and Guo H. Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits. Expert Rev Cardiovasc Ther 3 (2005) 571-590
13. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 322 (1990) 863-868
14. Hart R.G., Halperin J.L., Pearce L.A., et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 138 (2003) 831-838
15. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 279 (1998) 1273-1277
16. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343 (1994) 687-691
17. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912
18. Halperin J.L. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol 45 (2005) 1-9
19. Albers G.W., Diener H.C., Frison L., et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293 (2005) 690-698
20. Olsson S.B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362 (2003) 1691-1698
21. Bousser M.G., Bouthier J., Buller H.R., et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371 (2008) 315-321
22. Kubitza D., and Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 15 (2006) 843-855
23. Piccini J.P., Patel M.R., Mahaffey K.W., et al. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs 17 (2008) 925-937
24. Usman M.H., Notaro L.A., Patel H., et al. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med 10 (2008) 388-397
25. Grogan M., Smith H.C., Gersh B.J., et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 69 (1992) 1570-1573
26. Packer D.L., Bardy G.H., Worley S.J., et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 57 (1986) 563-570
27. Nerheim P., Birger-Botkin S., Piracha L., et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110 (2004) 247-252
28. Farshi R., Kistner D., Sarma J.S., et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 33 (1999) 304-310
29. Olshansky B., Rosenfeld L.E., Warner A.L., et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43 (2004) 1201-1208
30. Van Gelder I.C., Wyse D.G., Chandler M.L., et al. Does intensity of rate-control influence outcome in atrial fibrillation?. An analysis of pooled data from the RACE and AFFIRM studies. Europace 8 (2006) 935-942
31. Van Gelder I.C., Van Veldhuisen D.J., Crijns H.J., et al. RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J 152 (2006) 420-426
32. Gasparini M., Auricchio A., Metra M., et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 29 (2008) 1644-1652
33. Gasparini M., Auricchio A., Regoli F., et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 48 (2006) 734-743
34. Hamdan M.H., Freedman R.A., Gilbert E.M., et al. Atrioventricular junction ablation followed by resynchronization therapy in patients with congestive heart failure and atrial fibrillation (AVERT-AF) study design. Pacing Clin Electrophysiol 29 (2006) 1081-1088
35. Khan M.N., Jais P., Cummings J., Di Biase L., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359 (2008) 1778-1785
36. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
37. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002) 1834-1840
38. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 (2008) 2667-2677
39. Corley S.D., Epstein A.E., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109 (2004) 1509-1513
40. Pedersen O.D., Brendorp B., Elming H., et al. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction?. Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. Card Electrophysiol Rev 7 (2003) 220-224
41. Olshansky B., Heller E.N., Mitchell L.B., et al. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke?. Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol 45 (2005) 2026-2033
42. Botkin S.B., Dhanekula L.S., and Olshansky B. Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J 145 (2003) 233-238
43. Fragakis N., Bikias A., Delithanasis I., et al. Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate. Europace 11 (2009) 70-74
44. Gopinathannair R., and Olshansky B. Ibutilide revisited: stronger and safer than ever. Europace 11 (2009) 9-10
45. Konety S.H., and Olshansky B. The "pill-in-the-pocket" approach to atrial fibrillation. N Engl J Med 352 (2005) 1150-1151
46. Alboni P., Botto G.L., Baldi N., et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 351 (2004) 2384-2391
47. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 4 (2007) CD005049
48. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342 (2000) 913-920
49. Singh B.N., Singh S.N., Reda D.J., et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 (2005) 1861-1872
50. Garguichevich J.J., Ramos J.L., Gambarte A., et al. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). Am Heart J 130 3 Pt 1 (1995) 494-500
51. Doval H.C., Nul D.R., Grancelli H.O., et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344 (1994) 493-498
52. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
53. Ceremuzynski L., Kleczar E., Krzeminska-Pakula M., et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 20 (1992) 1056-1062
54. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 333 (1995) 77-82
55. Savelieva I., and Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 10 (2008) 647-665
56. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
57. Savelieva I., and Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 5 (2008) 30-41
58. Ehrlich J.R., and Nattel S. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. Curr Opin Cardiol 24 (2009) 50-55
59. Camm A.J., and Savelieva I. New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant. J Interv Card Electrophysiol 23 (2008) 7-14
60. Naccarelli G.V., Wolbrette D.L., Samii S., et al. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther 5 (2007) 707-714
61. Roy D., Pratt C.M., Torp-Pedersen C., et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117 (2008) 1518-1525
62. Page R.L., Pritchett E.L., Connolly S., et al. Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. J Cardiovasc Electrophysiol 19 (2008) 172-177
63. Bode F., Sachs F., and Franz M.R. Tarantula peptide inhibits atrial fibrillation. Nature 409 (2001) 35-36
64. Coletta A.P., Cleland J.G., Cullington D., et al. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. Eur J Heart Fail 10 (2008) 917-920
65. Kober L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358 (2008) 2678-2687
66. Nair G.M., Nery P.B., Diwakaramenon S., et al. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J Cardiovasc Electrophysiol 20 (2009) 138-144